Skip to Content

Press Releases

Date Title Additional Format
Aug 03, 2006
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior
Jul 26, 2006
Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results
- VX-950 Global Phase 2b Clinical Development Plan On Track -
- Collaboration with Janssen Pharmaceutica, a Johnson & Johnson Company, Adds Important Strengths
and Development Capabilities for VX-950 -
Jun 30, 2006
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
Jun 30, 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex
May 23, 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naïve HCV Patients
- PROVE 1 & PROVE 2 Studies Expected to Enroll 580 Patients -
May 21, 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
- 12 of 12 (100%) patients HCV RNA undetectable with no evidence of viral breakthrough at end of 28 days VX-950 dosing -
- 92% (11 of 12) continued to have undetectable HCV RNA through 12 weeks of follow-on therapy -
May 17, 2006
Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis
- FDA Grants Fast Track Designation to VX-770 -
May 16, 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and
May 11, 2006
Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
- Company Updates Corporate Governance Practices -
Apr 29, 2006
Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients
-New data show that plasma HCV RNA levels were below limit of detection (10 IU/mL) in 8 of 8 patients continued on peg-IFN+RBV for 12 weeks-
Apr 26, 2006
New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950
Results to be Presented at 41st Annual Meeting of the European Association for the Study of the Liver
Apr 25, 2006
Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
–– Company on Track to Achieve Clinical, Research and Corporate Objectives ––
Apr 05, 2006
Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
- Vertex earns $10 million milestone payment -
Mar 23, 2006
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF Cambridge, MA, March 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.
Mar 08, 2006
Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis
--Vertex to Advance Clinical Program; Company Expects to Initiate Combination Study of VX-702 and Methotrexate by Mid-2006--
Feb 23, 2006
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference Cambridge, MA, February 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Citigroup 2006 Healthcare Conference in Washington, DC.
Feb 07, 2006
Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program
-Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study-
Feb 06, 2006
Vertex Pharmaceuticals Reports 2005 Financial Results
- Clinical, Research and Financial Objectives Achieved -
Jan 12, 2006
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.
Jan 09, 2006
Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
—Product Candidates with Transformational Potential Highlighted—
Displaying 721 - 740 of 825